A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Recruiting
Phase 2
Phase 3
Interventional Study
Lichen Planopilaris
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 342 (estimated)
- Sponsor
- Priovant Therapeutics, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age ≥ 18 years
2. Scalp biopsy consistent with LPP
3. Active and symptomatic LPP at screening and baseline-
4. Weight \> 40 kg to \< 130 kg with BMI ≤ 45 kg/m2
Exclusion Criteria:
1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 yea…
Contacts